Oo Than N, Roberts Tricia L, Collins Allan J
Kalamazoo Center for Medical Studies, Michigan State University, Kalamazoo, MI, USA.
Am J Kidney Dis. 2005 Feb;45(2):372-80. doi: 10.1053/j.ajkd.2004.10.008.
Previous comparisons of peritonitis rates between continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD) have produced varying results.
Using United States Renal Data System data, the authors evaluated peritonitis rates in 1994 through 1997 incident CAPD (n = 9,190) and CCPD (n = 2,785) Medicare patients. Patients were characterized during a 6-month entry period (months 4 through 9) and followed for a maximum of 2 years (months 10 through 33). Medicare claims data provided the date of the first peritonitis episode during the follow-up period. The time to first peritonitis after 9 months of PD was compared by the log-rank test, and then by Cox regression with adjustment for peritoneal dialysis modality, age, sex, race, primary end-stage renal disease (ESRD) diagnosis, number of entry-period hospital days, peritonitis during the entry period, hematocrit value, and congestive heart failure.
For CAPD and CCPD, the adjusted average months to first peritonitis after 9 months of PD were 17.1 and 16.1, respectively. The probabilities of remaining without a peritonitis episode after 1 year of follow-up were 0.53 and 0.50, respectively ( P = 0.008). The risk of peritonitis was lower for CAPD than for CCPD (relative risk, 0.939; 95% confidence interval, 0.883 to 0.998). Other significant risk factors included age <or=44 years, black race, diabetes as primary ESRD diagnosis, peritonitis during the entry period, greater than 4 entry-period hospital days, and congestive heart failure. Patients treated with recombinant human erythropoietin with a hematocrit value of >or=36% had lower risk of peritonitis.
Compared with CCPD, CAPD is associated with a slightly but significantly lower risk for development of a first peritonitis episode after 9 months of peritoneal dialysis therapy.
以往对持续性非卧床腹膜透析(CAPD)和持续性循环腹膜透析(CCPD)腹膜炎发生率的比较结果各异。
作者利用美国肾脏数据系统的数据,评估了1994年至1997年开始接受CAPD(n = 9190)和CCPD(n = 2785)治疗的老年医疗保险患者的腹膜炎发生率。在6个月的入组期(第4至9个月)对患者进行特征描述,并随访最长2年(第10至33个月)。老年医疗保险理赔数据提供了随访期内首次发生腹膜炎的日期。采用对数秩检验比较腹膜透析9个月后至首次发生腹膜炎的时间,然后通过Cox回归分析,并对腹膜透析方式、年龄、性别、种族、原发性终末期肾病(ESRD)诊断、入组期住院天数、入组期腹膜炎、血细胞比容值和充血性心力衰竭进行校正。
对于CAPD和CCPD,腹膜透析9个月后至首次发生腹膜炎的校正平均月数分别为17.1和16.1。随访1年后未发生腹膜炎的概率分别为0.53和0.50(P = 0.008)。CAPD发生腹膜炎的风险低于CCPD(相对风险,0.939;95%置信区间,0.883至0.998)。其他显著的风险因素包括年龄≤44岁、黑人种族、糖尿病作为原发性ESRD诊断、入组期腹膜炎、入组期住院天数超过4天以及充血性心力衰竭。接受重组人促红细胞生成素治疗且血细胞比容值≥36%的患者发生腹膜炎的风险较低。
与CCPD相比,CAPD在腹膜透析治疗9个月后首次发生腹膜炎的风险略低但显著降低。